A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Solid Tumors
||Calithera Biosciences, Inc
||Male and Female Patients
|U.S. Govt. ID:
||Kristina Lora: 646-317-5381 / ETCReferral@columbia.edu
This study is for patients with the following types of cancer: Triple negative breast cancer, non-small cell lung cancer, mesothelioma, renal cell carcinoma, melanoma, head and and neck squamous cell carcinoma, colorectal cancer, sarcoma and pancreatic cancer. The purpose of this study is to evaluate the effectiveness of the study drug CB-839 in helping patients with an advanced stage of cancer. The study will examine how the study drug is distributed, broken down and passed out of your body and will also identify the highest dose that can be given without causing severe side effects.
This study is closed
Richard Carvajal, MD
|Do you have an advanced tumor that is relapsed and is not responsive to any available therapy?
|Do you have any other current or previous malignancy?